Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of “Buy” by Brokerages

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been given a consensus rating of “Buy” by the fifteen analysts that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $100.25.

A number of equities research analysts have issued reports on the company. Cowen initiated coverage on Mirum Pharmaceuticals in a research report on Wednesday, September 24th. They set a “buy” rating for the company. Robert W. Baird increased their target price on shares of Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Citizens Jmp raised their price target on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a report on Friday, December 19th. Morgan Stanley lifted their price target on shares of Mirum Pharmaceuticals from $81.00 to $95.00 and gave the company an “overweight” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research report on Wednesday, October 8th.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $80.21 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The firm has a market capitalization of $4.12 billion, a price-to-earnings ratio of -93.27 and a beta of 0.42. Mirum Pharmaceuticals has a one year low of $36.88 and a one year high of $82.58. The company has a 50 day moving average price of $71.29 and a 200 day moving average price of $66.12.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.15. The company had revenue of $133.01 million during the quarter, compared to analysts’ expectations of $130.11 million. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The business’s quarterly revenue was up 47.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.30) EPS. Sell-side analysts anticipate that Mirum Pharmaceuticals will post -1.43 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in MIRM. MCF Advisors LLC grew its stake in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares in the last quarter. Quantbot Technologies LP acquired a new stake in Mirum Pharmaceuticals in the third quarter valued at approximately $33,000. Quarry LP acquired a new stake in Mirum Pharmaceuticals in the third quarter valued at approximately $41,000. CWM LLC raised its stake in shares of Mirum Pharmaceuticals by 30.8% during the third quarter. CWM LLC now owns 683 shares of the company’s stock valued at $50,000 after purchasing an additional 161 shares during the period. Finally, Comerica Bank lifted its position in shares of Mirum Pharmaceuticals by 45.1% during the first quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.